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Background. Systemic sclerosis is an autoimmune disease, characterized by widespread small vessel vasculopathy, immune
dysregulation with production of autoantibodies, and progressive fibrosis. Changes in levels of proangiogenic cytokines had already
been determined largely in serum. Our aim was to assess the levels of VEGF in human tears of patients with SSC. Patients and
methods. Forty-three patients (40 female and 3 men, mean (SD) age 61 (48–74) years) with SSc and 27 healthy controls were
enrolled in this study. Basal tear sample collection and tear velocity investigations were carried out followed by an ophthalmological
examination. Total protein concentrations and VEGF levels were determined in tear samples. Results. The average collected tear
fluid volume developed 10.4 𝜇L (1.6–31.2) in patients and 15.63 𝜇L (3.68–34.5) in control subjects. The average total protein level
was 6.9 𝜇g/𝜇L (1.8–12.3) in tears of patients and control tears contained an average of 4.132𝜇g/𝜇L (0.1–14.1) protein. In patients with
SSc the average concentration of VEGF was 4.9 pg/𝜇L (3.5–8.1) and 6.15 pg/𝜇L (3.84–12.3) in healthy samples. Conclusions. Total
protein production was increased because of the smaller tear volume. Decreased VEGF in tear of SSc patients can be explained also
by the decreased tear secretion of patients.
1. Introduction
Systemic sclerosis (SSc or scleroderma) is a chronic con-
nective tissue disorder which affects mostly the skin and
multiple internal organs, including the heart, lung, kidneys,
and gastrointestinal tract. SSc is a systemic autoimmune dis-
ease characterized by widespread small vessel vasculopathy,
immune dysregulation with production of autoantibodies,
and progressive fibrosis [1].
There are only few reports available on the ophthalmo-
logical complications during the course of systemic scle-
rosis. Changes in the organ of vision are thought to be
the consequence of systemic complications of scleroderma
or adverse effects of immunosuppressive treatment applied.
Ocular symptoms may occur at any stage of the disease and
may involve numerous ocular tissues. Their course can be
clinically latent or very intensive. The most common clinical
manifestations of soft tissue fibrosis and inflammation in
these patients include increased tonus and telangiectasia
of eyelid skin. The most commonly reported lesions are
periorbital edema, palpebral ectropion, and ciliarymadarosis
[2]. In our study the most frequent ocular manifestation of
SSc was dry eye syndrome (DES).
DES is a major healthcare problem since it affects the
patients’ quality of life. DES was recently redefined as a mul-
tifactorial disease of the tears and ocular surface that results
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in symptoms of discomfort, visual disturbance, and tear film
instability and after all damage to the ocular surface [3].
Increased osmolality of the tear film [4] and inflammation
of the ocular surface [5] are the two major characteristic
points in DES. Increased levels of several inflammatory
cytokines are the most important laboratory findings [6].
Accordingly, tear cytokine levels are already considered as
potential markers of inflammation in DES.
Although the exact origin of SSc is unknown, some pre-
disposing factors—like environmental and infectious agents,
tissue injury, and hypoxia or oxidative stress on a suscep-
tible genetic background—may play a role in the disease
development [1, 7]. One of the earliest clinical manifestations
in the pathophysiology of SSc is vascular injury that can
be caused by the imperfect angiogenesis due to impaired
production of proangiogenic factors. Vascular endothelial
growth factor (VEGF) is one of the most important proan-
giogenic factors which play a key role in the formation of
new blood vessels [8]. VEGF takes part in various steps of
angiogenesis, including initial vasodilation, endothelial cell
permeability, perivascular matrix remodeling, and induction
of proliferation and migration of endothelial cells [9].
Although tear analysis is of increasing interest in ophthal-
mology, yet no studies have investigated tears of SSc patients,
possibly because of its technical challenge due to the small
sample volumes available [10].
The aim of this study was to demonstrate a significant
difference of VEGF levels in human tears of SSc patients
compared to healthy controls. Since tear dynamically reflects
the factors present at the ocular surface, this is an ideal sample
to investigate; furthermore, it has the potential for earlier
diagnosis of SSc with a noninvasive method of collecting
samples.
2. Materials and Methods
2.1. Patients and Healthy Controls. Forty-three patients with
SSc and 27 healthy controls were included in our study.
Patients were enrolled from the outpatient clinic at the
Department of Rheumatology, Department of Ophthalmol-
ogy (40 female and 3 men), mean (SD) age 61 (48–74) years.
SSc was diagnosed based on the corresponding international
criteria [11, 12].
They went through ophthalmological examination and
basal tear sample collection at the Department of Ophthal-
mology during a 12-month period. DES was diagnosed in
32 of 43 SSc patients. All patients have undergone a broad
immunoserological screening, including ANA, anti-SSA,
anti-SSB, corresponding ophthalmological tests, and salivary
measurement, which excluded the presence of coexisting
secondary Sjogren’s syndrome.
We enrolled 27 volunteers (21 female and 6 men) as
healthy controls who had no history of any autoimmune or
ocular disorder. Patients did not take immunosuppressive
medications at the time of the tear sampling.
Written informed consent was obtained from all patients
and controls. Study protocol was approved by the local
bioethics committee and followed the tenets of the declara-
tion of Helsinki.
2.2. Tear Sample Collection. Open eye tears were gently
collected from the inferior temporal meniscus of both eyes
using a capillary micropipette (Haematokrit-Kapillaren, Na-
Heparin 3.0 IU/kapillare, 75mm/60𝜇L, Hischmann Laborg-
erate), minimizing irritation of the ocular surface or lid mar-
gin as much as possible. All samples were collected between
11 am and 16 pmby the same physician. Tear secretion velocity
was counted by dividing the volume of collected sample by
time of secretion. Volume was calculated from the lengths
of the fluid column in the capillary tube, measured with a
vernier caliper, and from the known diameter of the tube.
Time of tear collection was measured with stopwatch. Tears
were transferred into low binding capacity Eppendorf tubes
by washing out the capillaries five times with PBS-T buffer
equal to the volume of tears. Fivefold diluted samples were
stored at −80∘C until assessment.
2.3. Tear Sample Preparation and Quantification. First, as a
point of reference for VEGF, total protein concentrations
were determined in tear samples with the BCA Microplate
method (Sigma-Aldrich, St. Louis, MO, USA) according to
themanufacturer’s instructions. Human albumin was used as
standard.
For the quantitative determination of VEGF in tear fluid
we used a human VEGF immunoassay kit by Quantikine
(R&D Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions. This assay employs the quanti-
tative sandwich enzyme immunoassay technique.
3. Statistical Analyses
Prism 5 statistical software (GraphPad Software Inc.) was
used for statistical analyses. Comparison of valueswas carried
out by Mann-Whitney 𝑈 test. All values are shown as
the mean ± SD. 𝑃 values less than 0.05 were considered
statistically significant.
4. Results
The average tear secretion velocity in patients was
4.53 𝜇L/min, with a median of 3.8𝜇L/min (1.5–25.6).
Duration of tear sample collection from patients changed
between 20 and 313 seconds until theminimally required 5𝜇L
volume was reached.
The average collected tear fluid volume developed 10.4 𝜇L
(1.6–31.2) in case of patients and 15.63 𝜇L (3.68–34.5) in case
of controls.
In tear samples of patients with SSc the average total
protein level was 6.9𝜇g/𝜇L (1.8–12.3) and the average concen-
tration of VEGF was 4.9 pg/𝜇L (3.5–8.1) in case of basal tear
secretion (Figure 1).
Control tears contained an average of 4.132 𝜇g/𝜇L (0.1–
14.1) protein and 6.15 pg/𝜇L (3.84–12.3) VEGF (Figure 2).
5. Discussion
Systemic sclerosis is an autoimmune disease affecting the
connective tissue and characterized by a wide spectrum of
microvascular and immunological abnormalities, leading to















Figure 1: VEGF concentrations (ng/mL) in tears of healthy controls















Figure 2: Total protein concentrations (mg/mL) in tears of healthy
controls (left) and SSc patients (right).
progressive fibrosis of the skin and other visceral organs, such
as lungs, gastrointestinal tract, heart, and kidneys [13]. Many
ocular manifestations of SSc have been described including
conjunctival telangiectasia, DES, and filamentous keratitis
[14].
DES in SSc is believed to be caused by fibrosis-related
impairment of lacrimal gland secretion, namely, the water
portion of the tear film. Furthermore, the lipid layer disorder
is caused by chronic blepharitis and meibomian gland dys-
function (MGD), and also the increased evaporation of tears
from the ocular surface is the consequence of the restricted
eyelid mobility and the consecutive reduced blinking [15].
Tear plays an essential role in maintaining homeostasis
of the ocular surface; therefore changes in the delicate
equilibrium of its cytokine composition may lead to various
pathophysiological conditions.
The influence of VEGF in ophthalmic diseases is pro-
found. It has been implicated in a large number of retinal
diseases and conditions like age-related macular degener-
ation and diabetic retinopathy, retinopathy of prematurity,
sickle cell retinopathy, and retinal vascular occlusion. VEGF
has secondary influence in neovascular glaucoma [16] and
inherited retinal dystrophies [17]. Since it has been discovered
in the 1980s [18] VEGF has raised interest because of its
central role in angiogenesis in a number of physiologic and
pathologic processes, such as vascular development, wound
healing, the female reproductive cycle, cancers, myocardial
ischemia, rheumatoid arthritis, and other autoimmune dis-
eases. VEGF is a component of normal tear fluid. Vesalu-
oma determined VEGF concentrations in healthy tears.
The median VEGF concentration was 5 pg/𝜇L (4–11) which
corresponds with our results, as control tears contained an
average of 6.15 pg/𝜇L (3.84–12.3) VEGF. Vesaluoma and co-
workers calculated the average tear fluid secretion in healthy
controls, which was 8.1𝜇L/min (0.7–20.8), using the same
tear collecting method as we used in our study. Results show
that SSc patients have significantly decreased tear secretion
that could be explained by DES, which is a probable sequel of
the disease or of the side effects of the therapeutic drugs [19].
Tear secretion velocity was lower by 67% in SSc patients
than in healthy controls. The difference was significant (𝑃 <
0.01). The reason for this sign could be explained by the
pathophysiology of the disease, namely, fibrotic processes.
Total protein values in SSc patients were higher by 42%
than in healthy controls. It may indicate that total protein
production—or simply the protein concentration, since SSc
patients have a decreased tear secretion velocity—is only
increased because of the smaller tear volume. Though VEGF
in tear of SSc patients was decreased by 20% and did not
change after stimulation, it can be explained also by the
decreased tear secretion of patients.
Although the average VEGF level in tear collected with-
out stimulation was higher than that in tear collected with
stimulation in SSc patients, the difference was not significant.
The phenomenon why the VEGF levels are not higher in




DES: Dry eye syndrome
MGD: Meibomian gland dysfunction
VEGF: Vascular endothelial growth factor
MMP: Matrix metalloproteinase
MCP: Monocyte chemoattractant protein
IL: Interleukin
IP: Interferon gamma-induced protein
TNF: Tumor necrosis factor
FasL: Fas ligand.
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